RYH0.F SAREUM HLDGS LS-0125
- Market cap
- EUR 23.4M
- P/E
- -
- P/B
- 14.45x
- ROE
- -194.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2025.
Is RYH0.F undervalued?
Graham numberThe Graham number of SAREUM HLDGS LS-0125 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SAREUM HLDGS LS-0125 fundamental analysis
No fundamental analysis for SAREUM HLDGS LS-0125 yet.
SAREUM HLDGS LS-0125 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SAREUM HLDGS LS-0125
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-sta…
Full company profileSAREUM HLDGS LS-0125 financial statements
SAREUM HLDGS LS-0125 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.58M | -4.05M | -4.57M | -3.38M |
| EBITDA | -2.58M | -4.05M | -4.57M | -3.38M |
| Net Income | -2.17M | -3.19M | -3.42M | -4.44M |
| EPS | -0.03 | -0.05 | -0.03 | -0.03 |
| Balance Sheet | ||||
| Total Assets | 4.79M | 2.02M | 2.77M | 4.23M |
| Total Liabilities | 455K | 867K | 653K | 1.95M |
| Shareholders' Equity | 4.33M | 1.15M | 2.11M | 2.28M |
| Cash & Short-term Investments | 4.26M | 994K | 1.46M | 3.55M |
| Cash Flow | ||||
| Operating Cash Flow | -2.13M | -3.27M | -3.92M | -2.55M |
| Capital Expenditure | 3.00K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.13M | -3.27M | -3.92M | -2.55M |
| Ratios | ||||
| ROE | -50.2% | -276.8% | -161.8% | -194.9% |
| ROA | -45.4% | -158.0% | -123.6% | -104.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
SAREUM HLDGS LS-0125 dividends
SAREUM HLDGS LS-0125 has not paid dividends in the last 4 fiscal years.
Last stock split: 1:50 on Mar 1, 2022.
Who owns SAREUM HLDGS LS-0125
- Insiders 3.31%
- Institutions 0.00%
- Public & others 96.69%
- Shares outstanding 164M
- Free float 133M
SAREUM HLDGS LS-0125 company profile
- Company name
- SAREUM HLDGS LS-0125
- Ticker
- RYH0.F
- ISIN
- GB00BMC3RJ87
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- June
- Address
- Langford Arch, Cambridge, United Kingdom, CB22 3FX
- Phone
- 44 1223 497 700
- Website
- sareum.com
About SAREUM HLDGS LS-0125
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company has strategic collaboration with Receptor.AI launched in August 2025 to accelerate discovery and optimisation of BBB-permeable TYK2/JAK1 inhibitors; and completion of initial stage expected Q4 2025. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
SAREUM HLDGS LS-0125 management
5- Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.Executive Chairman · born 1958
- Dr. John Charles Reader Ph.D.Founder, Chief Scientific Officer & Executive Director · born 1967
- Dr. Timothy John Mitchell Ph.D.Founder, COO & Executive Director · born 1960
- Mr. Clive H. W. Birch F.C.A.Secretary & Senior Independent Non-Executive Director · born 1953
- Alexandra HarrisonHead of IR